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Introduction
Bladder cancer is the fourth most common cancer in men and the eighth most common malignancy in women in the United States according to the American Cancer Society (1) . In general, bladder cancer is curable when detected and treated early; therefore, a more accurate early diagnosis of bladder cancer would be advantageous. Bladder cancer in dogs is the most common tumor of the urinary tract and comprises about 1% of all canine cancers (2) . Canine transitional cell carcinoma (K9TCC) closely resembles human invasive urinary bladder cancer (3) . Urinary bladder tumors in dogs are usually malignant with only 3% of tumors being benign.
Sensitivity and specificity of conventional cystoscopy of bladder tumors can be significantly improved by using tumor-specific agents (4) . In contrast to cyclooxygenase (COX) -1, COX-2 is not expressed in most normal tissues, but rather is induced in inflamed tissues and in many carcinomas (5) (6) (7) (8) (9) (10) (11) . COX-2 expression significantly increases with human urinary bladder tumor stage, comparing muscle-invasive tumors to superficially invasive tumors (12, 13) .
COX-2 is undetectable in human normal urinary bladder 0/10, but COX-2 is expressed in 29/29 of bladder squamous cell carcinomas (SCC), and in 12/35 (34%) of TCC (12, 14) . Genetically modified COX-2 -/-mice exhibit decreased incidence of intestinal and skin tumors (15, 16) .
Numerous pharmacological studies validate COX-2 as a therapeutic target to control the inflammation and tumorigenesis (5, 17, 18) . Thus, newly synthesized non-steroidal antiinflammatory drugs (NSAIDs) are attractive not only as pharmacological and chemo-preventive agents, but now also as a new family of imaging agents (19, 20) .
The use of the COX-2 selective inhibitors as a new class of imaging agents is based on the selective uptake by COX-2-expressing neoplastic lesions. The first synthesis and characterization of radioactively-labeled COXIBs as cancer imaging agents have been reported (21,22). As we published previously, promising results were obtained using a derivative of celecoxib as a SPECT radiotracer to identify COX-2-expressing, carcinogen-induced, lung and pancreatic lesions in hamsters (22) . Additional novel PET and SPECT imaging radiotracers were later synthesized and evaluated in cancers and inflammation rodent models (23, 24) . Novel synthesized derivatives of NSAIDs labeled with rhodamine dyes have been evaluated as optical imaging agents for detection of COX-2 expressing inflammation and cancer in rodents (25, 26) .
One of the most promising optical imaging agent that selectively binds to COX-2 called fluorocoxib A, N-[(5-carboxy-X-rhodaminyl)but-4-yl]-2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-
1H-indol-3-yl]acetamide (λ ex = 580 nm and λ em = 605 nm) (25) . Fluorocoxib A is a weak inhibitor of purified ovine COX-1 and a strong inhibitor of purified human COX-2 enzyme (IC 50 =25 µM, IC 50 = 0.7 µM; respectively). Fluorocoxib A inhibits LPS-and IFNγ-induced COX-2 activity in murine macrophage-like cells RAW264.7 (IC 50 = 0.31 µM) (25, 26) . Fluorocoxib A was evaluated using carrageenan-induced acute inflammation in the mouse footpad, human tumor xenografts in nude mice, and in mice with spontaneous tumors (25) in vivo. Human colorectal cancer HCT-116 xenografts that do not express COX-2, exhibit minimal fluorescence, whereas the human SCC 1483 xenografts with high levels of COX-2 expression, exhibited bright fluorescence after fluorocoxib A administration (25) . Nude mice with 1483 xenografts pretreated with indomethacin (2 mg/kg, i.p.) 2 h before fluorocoxib A administration (2 mg/kg, i.p.) show 92 ± 6% (n = 8) reduction of the fluorocoxib A uptake in these tumors (25) . In addition, the COX-2 non-targeted fluorophores, such as 5-ROX and 6-ROX alone, did not accumulate in COX-2-expressing tumor xenografts, supporting specificity of fluorocoxib A uptake in COX-2-expressing tumors in vivo.
Material and methods
Fluorocoxib A was synthesized according to the previously described method (25, 26) . The chemical structure of fluorocoxib A is shown in Figure 1 .
Antibodies and other reagents -Antibody for COX-2 were obtained from Cayman Chemical Corporation (Ann Arbor, MI); E-cadherin and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); F4/80 was obtained from Abcam (Cambridge, MA); phosphorylated p-65 (p-p65) was obtained from BD Biosciences (San Jose, CA); lysozyme and cytokeratin were purchased from Dako (Carpinteria, CA).
Human cell lines -Human transitional cell carcinomas T-24 and UMUC-3 were purchased from
American Type Culture Collection (ATCC, Manassas, VA) in 2010. Human T-24 cells were maintained in McCoy's media, and human UMUC-3 cells were maintained in EMEM media; respectively, supplemented with 10% fetal bovine serum, 100 I.U. penicillin, and 100 μg/ml streptomycin and grown in an atmosphere of 5% CO 2 at 37°C. Cell lines were authenticated via short tandem repeat (STR) DNA profiling by Genetica DNA laboratories (Burlington, NC) just prior manuscript submission. To prove the specificity of fluorocoxib A binding to COX-2 expressing TCC in vivo, we performed two additional experiments using COX-2 expressing K9TCC#2Dakota in xenograft mice pretreated with selective COX-2 inhibitor -celecoxib (10 mg/kg) 4 h before injecting with fluorocoxib A (1 mg/kg). In addition, we used UMUC-3 human TCC with no COX-2 expression.
Isolation of primary K9TCC cells
The xenograft tumors were imaged up to 24 h post-injection with fluorocoxib A using IVIS system. The normalized averaged radiance of each tissue to blood was evaluated and compared between groups. After imaging, tissues were formalin-fixed and paraffin-embedded for histological analysis. Histology and expression of COX-2 and E-cadherin in K9TCC#2Dakota
and UMUC-3 xenograft tumors were assessed by IHC analysis.
Fluorocoxib A uptake by heterogeneous K9TCC during cystoscopy -All cystoscopy and imaging procedures in dogs were performed by a board-certified veterinary internal medicine specialist (JWB) in accordance with standard veterinary care and the UTIACUC approved protocol as described previously (27) . Five client-owned female dogs with bladder cancer lesions were enrolled in our study. The owners signed a consent form to agree enrolling their pets to this study to evaluate fluorocoxib A uptake in TCC during cystoscopy. Fluorocoxib A was administrated i.v. 1mg/kg over 20 min using a catheter, followed by up to 24 h uptake by COX-2 expressing bladder tumor cells. The concentration of fluorocoxib A (1 mg/kg) was determined based on results from our pharmacokinetic and safety studies (27) . Cystoscopy was used to evaluate the bladder cancer lesion, specificity of fluorocoxib A uptake, to obtain biopsy samples for diagnosis. The client-owned dogs were returned to owners after complete recovery from the cystoscopic examination and anesthesia.
Cancer Research. Immunohistochemistry -Xenograft tumors from athymic mice and primary tumor biopsies from dogs with TCC were formalin-fixed paraffin-embedded and sectioned at 7 μm. After deparaffinization and re-hydration, the sections were stained for COX-2 (1:500 overnight at 4 °C), E-cadherin (1:500 overnight at 4 °C), cytokeratin (1:800 overnight at 4 °C), p-p65 (1:1,000 for 1 h at r.t.), F4/80 (1:500 for 30 min at r.t.), or lysozyme (1:400 for 30 min at r.t.) using IHC protocol as described previously (27) . Western Blotting -Human and canine TCC cells were cultured in media with or without serum for 24 h. The cells were lysed, proteins were extracted and used for detection of COX-2 expression following the WB protocol as described previously (27) .
Statistical Analysis -Statistical analyses of obtained data were performed using the Student's ttest. Results were considered statistically significant at *p<0.05, **p<0.01, and ***p<0.001. Figure 2A ). The expression of E-cadherin (brown color) is shown in Figure 2B to confirm the epithelial-cell origin of tested K9TCC. K9TCC showed reduced E-cadherin expression as compared to normal urothelium (inset in Figure 2B ) confirming one of the characteristic of invasive adenocarcinomas.
We evaluated the expression of COX-2 in the biopsies from dogs with acute and chronic inflammation (n=8). The histology of these tissues revealed mild edema and moderate multifocal inflammatory cell infiltrates that were predominantly composed of perivascular plasma cells, eosinophils, lymphocytes, neutrophils, and macrophages. No COX-2 expression was detected in submucosa and urothelium with neutrophilic and lymphocytic cells inflammation (Supplemental Figure S1 ). Only the infiltrating perivascular macrophages in the submucosa showed positive COX-2 expression (brown color) as shown in Figure 2C and 2D. We performed additional IHC for detection of F4/80 (macrophage marker), p-p65 (active p-p65, inflammatory marker) and lysozyme (macrophage marker) expressions in order to confirm the presence of inflammatory macrophages in the submucosa as shown in Figure 2E- Figure 3A , bright field using differential interference contrast microscopy, DIC) were incubated with 1 µM fluorocoxib A for 1 h and stained with COX-2 specific antibodies labeled with Alexa Fluor 488 dye. As shown in Figure 3B fluorocoxib A (red color) penetrated into the cytoplasm of K9TCC and specifically bound to COX-2 (green color) located at perinuclear areas as shown in Figure 3C . The nuclei of K9TCC were counterstained with DAPI staining (blue color) as shown in Figure 3D . Colocalization of COX-2 and fluorocoxib A uptake was confirmed by overlaying the images as shown in Figure 3E (yellow color). The overlaid image of fluorocoxib A, COX-2 and DAPI is shown in Figure 3F . as shown in Figures 5A(b) and 5B. Furthermore, UMUC-3 xenograft tumors showed no uptake of fluorocoxib A by tumors due to lack of COX-2 expression as shown in Figure 5A (c) and 5B. 
K9TCC#2Dakota xenograft tumors had positive perinuclear COX-2 expression in cells by IHC (brown color) as shown in Figure 5C(a) . Positive E-cadherin expression confirmed epithelial cell origin of TCC as shown in Figure 5C (b). Primary K9TCC#2Dakota tumor with confirmed COX-2 and E-cadherin expressions by IHC is shown in Supplemental Figure S2A(a, b) . The UMUC-3 xenograft tumors had no expression of COX-2, but had a positive E-cadherin expression as shown in Figure 5C(c, d) . The size of developed xenograft tumors using K9TCC#2Dakota and UMUC-3 in athymic mice over a 3-week period are shown in Supplemental Figure S2B(a, b) . In addition, we observed that UMUC3 tumors of approximately the same size were more vascularized than K9TCC xenograft tumors as shown in enlarged images of xenograft tumors in Supplemental Figure S2B . The expression of COX-2 was confirmed by western blot in primary K9TCC#2Dakota, but not in UMUC-3 cells as shown in Figure 5D . Taken together, these data showed that fluorocoxib A uptake was specific for COX-2 expressing tumors and fluorocoxib A was not accumulated in tumors due to increased vascular permeability in tumors. 
Detection of COX-2-expressed K9TCC by fluorocoxib A during cystoscopy using Karl
agent highly sensitive and selective for detection of COX-2-expressing tumors. Fluorocoxib A specifically bound to COX-2-expressing K9TCCs and allowed better visualization and identification of the COX-2 positive K9TCC as shown in Figure 6B (pink color). Additional approaches to prove the specificity of the fluorocoxib A uptake by COX-2 expressing K9TCC in vivo will be undertaken in future studies.
Tumor detection and characterization of COX-2 expression might be useful for COX-2-targeted treatments to increase the survival of canine (38) and human patients. Numerous studies have provided evidence that inhibition of COX-2 pathways may have significant benefits for cancer treatment and prevention (19,28,31,39-42), particularly in bladder cancer (41, (43) (44) (45) .
Interestingly, patients with COX-2 negative, non-small-cell lung cancer (NSCLC) fared worse if treated with celecoxib as adjuvant treatment to carboplatin and gemcitabine than patients given chemotherapy alone (46). None of the currently used imaging agents in clinic have the ability to detect COX-2-expressing tumors.
Although we only evaluated fluorocoxib A in bladder cancer; data obtained from this study can be useful for testing of fluorocoxib A in other types of COX-2-expressing cancers, such as breast, lung, pancreas, head and neck, and prostate carcinomas in dogs and people. In our previously published study, we have shown a specific uptake of fluorocoxib A in canine colorectal adenocarcinomas during colonoscopy in vivo (27) 
